Advertisement

Topics

Samsung Bioepis Co., Ltd. Company Profile

00:41 EDT 17th June 2019 | BioPortfolio

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to increasing patient access to affordable, high-quality biologic medicines. Through innovations in product development and quality assurance, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.


News Articles [163 Associated News Articles listed on BioPortfolio]

3SBio to Commercialize Multiple Samsung Bioepis Biosimilars in China

3SBio, a Shenyang biopharma, will partner with Samsung Bioepis, a Samsung BioLogics-Biogen JV, to develop and commercialize multiple Bioepis biosimilars (including an Avastin biosimilar) in mainland C...

Samsung Bioepis forms new alliance to expand in China

Samsung Bioepis has signed a licensing deal with healthcare-focused private equity firm C-Bridge Capital to accelerate expansion in mainland China....Read More... The post Samsung Bioepis forms new al...

Samsung Bioepis expands in China with second partner in two months

Samsung Bioepis announces licensing agreement with C-Bridge to bring âthird-waveâ biosimilars to the Chinese market.

Samsung Bioepis partner brings biosimilars to China

Samsung Bioepis will expand into the Chinese market after agreeing to a deal with 3SBio to commercialise its biosimilar portfolio.

Samsung Bioepis, C-Bridge Capital to Develop Next-Gen Biosims in China

C-Bridge forms new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis

Samsung Bioepis makes deals for copy biologicals in China

Samsung Bioepis has made deals with two Chinese firms to expand its business in the country.

Samsung Bioepis secures FDA approval for cancer drug Ontruzant

The US Food and Drug Administration (FDA) has granted approval for Samsung Bioepis to use Ontruzant (trastuzumab-dttb) to treat a...Read More... The post Samsung Bioepis secures FDA approval for cance...

FDA Approves Samsung Bioepis’ Eticovo, a Biosimilar to Enbrel

INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Renflexis [merck sharp & dohme corp.]

These highlights do not include all the information needed to use RENFLEXIS safely and effectively. See full prescribing information for RENFLEXIS. RENFLEXIS (infliximab-abda) for Injection, for Intra...

PubMed Articles [7 Associated PubMed Articles listed on BioPortfolio]

Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-center, observational, retrospective, real-life study.

The approval of the etanercept biosimilar SB4 (Brenzys, Benepali; Samsung Bioepis Co., Ltd.) for psoriasis and psoriatic arthritis (PsA) was automatically obtained on the basis of the demonstration of...

Comparative analysis of positioning accuracy of Samsung Galaxy smartphones in stationary measurements.

Achieving single meter positioning accuracy by portable mobile devices still poses a major challenge to the satellite signal receivers constructors, despite gradual constellation completing process an...

Computer-Aided Diagnosis of Solid Breast Lesions With Ultrasound: Factors Associated With False-negative and False-positive Results.

To investigate factors that may lead to false-positive or false-negative results in a computer-aided diagnostic system (S-Detect; Samsung Medison Co, Ltd, Seoul, Korea) for ultrasound (US) examination...

Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study.

Recent evidence suggests that alcoholic fatty liver disease (AFLD) and non-alcoholic fatty liver disease (NAFLD) may differentially affect risk of cardiovascular mortality. To investigate whether earl...

Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.

Previous studies have revealed that biliary tract cancer (BTC) has different clinical characteristics depending on its anatomical location. However, clinical studies about the prognosis of BTC accordi...

Clinical Trials [31 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting

To establish the performance characteristics of the Samsung LABGEO IVD-A20 CHF Test in intended use settings, by comparing test results of the A20 CHF Test with results obtained from an FD...

Gait Pattern Analysis and Feasibility of Gait Training With a Walking Assist Robot in Stroke Patients and Elderly Adults

The purpose of this study was to investigate the effects of the new wearable hip assist robot developed by Samsung Advanced Institute of Technology (Samsung Electronics Co, Ltd., Korea) to...

Effect of Gait Training With a Walking Assist Robot on Gait Function and Balance in Patients With Chronic Stroke

The purpose of this study was to investigate the effects of gait training with the new wearable hip assist robot developed by Samsung Advance Institute of Technology (Samsung Electronics C...

Effect of Gait Training With a Walking Assist Robot on Gait Function and Balance in Elderly Adults

The purpose of this study was to investigate the effects of gait training with the new wearable hip assist robot developed by Samsung Advance Institute of Technology (Samsung Electronics C...

Application of Cervical Elastography in Obstetrics

The purpose of this study is to develop cervical elastography nomograms using Samsung's novel technology "E-cervix" and determine its ability to predict preterm birth. During each sonogra...

Companies [25 Associated Companies listed on BioPortfolio]

Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to increasing patient access to affordable, high-quality biologic medicines. Through innovations in p...

Samsung Electronics America

Samsung Electronics America, Inc. (SEA), based in Ridgefield Park, NJ, is a subsidiary of Samsung Electronics Co., Ltd. The company markets a broad range of award-winning consumer...

Samsung Electronics North America

Samsung Electronics North America (NAHQ), based in Ridgefield Park, NJ, is an arm of Samsung Electronics Co., Ltd. The company markets a broad range of award-winning consumer elec...

Samsung Electronics America, Inc.

Samsung Electronics America, Inc. (SEA), based in Ridgefield Park, NJ, is a subsidiary of Samsung Electronics Co., Ltd. The company markets a broad range of award-winning consumer...

Samsung NEXT

Samsung NEXT builds, grows and scales transformative software and services to complement Samsung’s global hardware footprint. A leading driver of Samsung's transformation int...

More Information about "Samsung Bioepis Co., Ltd." on BioPortfolio

We have published hundreds of Samsung Bioepis Co., Ltd. news stories on BioPortfolio along with dozens of Samsung Bioepis Co., Ltd. Clinical Trials and PubMed Articles about Samsung Bioepis Co., Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Samsung Bioepis Co., Ltd. Companies in our database. You can also find out about relevant Samsung Bioepis Co., Ltd. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record